Merck KGaA and Versant Ventures Launch Saturnus Bio with Build-to-Buy Deal Targeting Rare Genetic Cardiomyopathies
Merck Group
Pharmaceutical R&D Developer
▲9July 4-5 CBI Biomedical Innovation Expo Scan the QR code to register
Note:This article does not constitute any investment advice or recommendations; please refer to official/company announcements for authoritative information.This article is for informational purposes only regarding medications related to medical health and does not constitute a recommendation for treatment plans (if any); it does not represent the platform’s position.Authorization is required for any article reprint.
Pharmaceutical Integration Circle DataMonitoringDisplay：On June 23, 2026, Saturnus Bio, a newly incubated biotechnology enterprise pioneering next-generation precision cardiology and focused on developing targeted gene regulation therapies, was established. The company is dedicated to addressing rare monogenic cardiomyopathies.
Merck KGaA and Versant Ventures adopt a customized “build-to-buy deal structure”transaction structure, co-founded Saturnus Bio.
Pursuant to the terms of the agreement,Merck KGaA to Pay $50 Million Upfront Cash Payment, fully covering all early-stage R&D activities of Saturnus Bio; additionally, tiered performance-based preclinical milestone payments will be made separately, triggered by phased progress in the development pipeline.
Merck KGaA will hold a minority stake in Saturnus Bio and secure an exclusive global option to acquire the company in full upon the achievement of predefined R&D milestones.
The entire acquisition consideration payable to Versant Ventures under the transaction is structured as performance-based contingent payments tied to clinical development milestones, with no product sales royalty provisions included in the overall consideration framework. Versant Ventures serves as the sole founding incubator and lead venture capital investor for this project.
Dr. Rick Dewey, Entrepreneur in Residence at Versant Ventures and CEO of Saturnus Bio, stated, “This foundational strategic collaboration with Merck KGaA and the incubation of Saturnus Bio exemplify Versant’s core strategy of partnering with leading pharmaceutical companies to build biotechnology enterprises from the ground up, addressing significant unmet clinical needs. The company is uniquely positioned to accelerate drug discovery and preclinical development of best-in-class therapies for patients with hereditary cardiomyopathy.”
Dr. David Weinreich, Global Head of Research and Development and Chief Medical Officer at Merck KGaA, stated: “This collaboration with Saturnus Bio enables us to accelerate the development of innovative precision cardiology therapies for patients with monogenic heart diseases—a rare disease population with significant unmet medical needs.”Leveraging Saturnus Bio’s professional expertise in cardiovascular genetics and its cutting-edge gene regulation technology platform, combined with Merck KGaA’s differentiated antibody engineering and translational medicine capabilities, we can pioneer new therapeutic technology pathways and deliver targeted treatment regimens to patients more rapidly.”
Follow the “YaoRongQuan” WeChat Official Account
References:
YaoRongQuan Data;
FDA/EMA；
NMPA；
https://www.merckgroup.com/en/news/merck-versant-launch-saturnus-23-6-2026.html；
https://www.sec.gov/Archives/edgar/data；
https://www.businesswire.com；
https://lifescivoice.com；
https://www.globenewswire.com/n
ews-release；
https://www.businesswire.com/news/home；
Wait.
